annb0t
Top 20
Immutep Limited
New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmark Constructive feedback from the US FDA regarding the clinical development program for efti in metastatic breast cancer (MBC) New interim data for 1st line NSCLC patients from TACTI-002 to be reported in a prestigious Oral Presentation at ASCO in June 2022 Phase IIb TACTI-003 patient recruitment advancin...
>>> Read more: Immutep Quarterly Activities Report
New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmark Constructive feedback from the US FDA regarding the clinical development program for efti in metastatic breast cancer (MBC) New interim data for 1st line NSCLC patients from TACTI-002 to be reported in a prestigious Oral Presentation at ASCO in June 2022 Phase IIb TACTI-003 patient recruitment advancin...
>>> Read more: Immutep Quarterly Activities Report
